Ocugen Announces Positive Preliminary Phase 2 Data for OCU410 Gene Therapy.

Ocugen announces positive preliminary data from Phase 2 of its OCU410 gene therapy trial for geographic atrophy secondary to dry age-related macular degeneration. The trial shows a 46% reduction in lesion growth compared to control at 12 months, with no serious adverse events reported. OCU410 is a novel modifier gene therapy designed to slow or halt the progression of GA.